Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Akira Yokomizo
Sign up to set email alerts
304
Publications
6,046
Citation Statements Received
5,618
Citation Statements Given
How they've been cited
7,742
259
5,746
41
How they cite others
6,560
341
5,240
37
Affiliations
Kyushu University
,
Harasanshin Hospital
Publications
Order By: Most citations
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Nam
1
,
Imai
2
,
Homet Moreno
3
et al.
2021
The Lancet Oncology
695
17
488
1
Get access via publisher
Add to collection
Cite
Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria
Katayama
1
,
Kurokawa
2
,
Nakamura
3
et al.
2015
Surg Today
Abstract
Show
840
1
427
0
Get access via publisher
Add to collection
Cite
Twist Promotes Tumor Cell Growth through YB-1 Expression
Shiota
1
,
Izumi
2
,
Onitsuka
3
et al.
2008
Abstract
Show
157
13
171
0
Get access via publisher
Add to collection
Cite
Alteration in Copy Numbers of Genes as a Mechanism for Acquired Drug Resistance
Yasui
1
,
Mihara
2
,
Zhao
3
et al.
2004
Abstract
Show
220
7
163
0
Get access via publisher
Add to collection
Cite
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Powles
1
,
Chang
2
,
Burgents
3
et al.
2022
The Lancet Oncology
307
5
157
4
2
Get access via publisher
Add to collection
Cite
Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression
Shiota
1
,
Yokomizo
2
,
Tada
3
et al.
2009
Oncogene
Abstract
Show
130
6
154
1
Get access via publisher
Add to collection
Cite
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
Chi
1
,
Nishiyama
2
,
Castellano
3
et al.
2017
The Lancet
Abstract
Show
176
6
125
1
Get access via publisher
Add to collection
Cite
Human acid ceramidase is overexpressed but not mutated in prostate cancer
Seelan
1
,
Qian
2
,
Yokomizo
3
et al.
2000
Genes Chromosom. Cancer
140
7
102
0
Get access via publisher
Add to collection
Cite
1
2
3
4
5
6